重组人干扰素α-2a凝胶治疗单纯疱疹双盲随机对照临床研究  

A Double-blind Randomized Controlled Clinical Trial of Recombinant Interferon α-2a Gel Versus Placebo in Treatment of Herpes Simplex

作　　者：汪科[1] 杨海珍[1] 李福秋[2] 白义杰[3] 徐金华[4] 朱学骏[1] 

机构地区：[1]北京大学第一医院皮肤性病科,北京100034 [2]吉林大学第二医院皮肤性病科,吉林长春130041 [3]辽宁省人民医院皮肤性病科,辽宁沈阳110015 [4]复旦大学附属华山医院皮肤性病科,上海200040

出　　处：《中国皮肤性病学杂志》2006年第12期734-736,共3页The Chinese Journal of Dermatovenereology

摘　　要：目的评价重组人干扰素α-2a凝胶治疗单纯疱疹的疗效和安全性。方法采用多中心、随机双盲、平行对照法对237例单纯疱疹患者进行了为期2周的临床试验。结果完成试验者共231例,试验组和对照组分别为117例和114例,重组人干扰素α-2a凝胶在治疗第3,7,10天时的痊愈率和有效率与安慰剂比较,均优于安慰剂组,差异均具有显著性意义。结论重组人干扰素α-2a凝胶治疗单纯疱疹疗效肯定,耐受性好,安全性高。Objective To study the efficacy and safety of recombinant interferon α-2a（rIFN-α2a） gel in the treatment of herpes simplex. Methods Clinical study was done on 237 cases of Herpes simplex for 2 weeks with a multiple-centre, randomized,double-bind,parallel trial. Results 231 cases have been studied. 117 were in the test group,114 were in controlled group respectively. The results showed that there was a significant different of cure rates and effective rates between therapeutic group and control group at day 3,7,10, The improved rates between the two groups had significant statistic differences. Conclusion Recombinant interferon α-2a gel is a topical drug with good efficacy, safety and tolerability in treatment of Herpes simplex.

关 键 词：重组人干扰素Α-2A 单纯疱疹 安慰剂对照 

分 类 号：R752.11[医药卫生—皮肤病学与性病学]